Treatments targeting inotropy

Area of Science:

• Cardiology and Pharmacology
• Mitochondrial Bioenergetics and Redox Regulation

Background:

• Acute heart failure (HF), especially cardiogenic shock, presents high mortality risks.
• Conventional positive inotropic agents (catecholamines, phosphodiesterase-inhibitors) are linked to increased mortality.
• Novel agents like levosimendan and omecamtiv mecarbil target sarcomeres, aiming to improve systolic function without raising intracellular Ca2+.

Purpose of the Study:

• To review the pathophysiological basis of systolic dysfunction in heart failure.
• To examine the mechanisms of action for various inotropic agents.
• To explore the impact of these agents on mitochondrial bioenergetics and redox regulation.

Main Methods:

• Review of existing literature on heart failure pathophysiology and inotropic agents.
• Analysis of clinical trial data for levosimendan and omecamtiv mecarbil.
• Discussion of the link between mitochondrial function, excitation-contraction coupling, and inotropic drug effects.

Main Results:

• Meta-analyses of smaller trials suggested levosimendan improved outcomes compared to dobutamine, but larger trials did not confirm this.
• Omecamtiv mecarbil shows a favorable hemodynamic profile in Phase II trials for acute and chronic HF.
• A Phase III trial for omecamtiv mecarbil in chronic HF is underway.

Conclusions:

• Identifying novel therapeutic targets is crucial for safely improving acute systolic and diastolic function in HF.
• Further research may lead to treatments that also enhance long-term myocardial structure and function.
• Understanding the impact on mitochondrial bioenergetics is key to developing safer inotropic strategies.